Most patients with early chronic myeloid leukemia (CML) achieve durable responses to treatment with imatinib, a specific inhibitor of BCR-ABL, the tyrosine kinase responsible for CML. However, relapse is frequent in patients with advanced disease and usually is the result of point mutations in the kinase domain (KD) of BCR-ABL. Unexpectedly, KD mutant clones were also detected in imatinib-na?ve patients, consistent with a growth advantage of mutants over wild type BCR-ABL in the absence of imatinib. Moreover, mutations in the ATP-binding loop of BCR-ABL confer a poor prognosis irrespective of their sensitivity to imatinib. These observations suggest that KD mutations may alter the biology of the CML in addition to and independent of their role in conferring imatinib resistance. Consistent with this, we have preliminary data that show differences in transformation potency between some mutants and wild type BCR-ABL. While these differences may be related to altered kinase activity in some cases, we have data showing that KD mutations also alter signal transduction. We propose to comprehensively analyze a panel of BCR-ABL mutants isolated from CML patients. We will determine kinetic parameters of kinase activity, activation of signaling pathways (using a novel extremely sensitive phosphoproteomics approach) and gene expression profiles, and correlate these data with transformation potency in biological assays. We will integrate this information to identify candidate mediators of a more or less aggressive phenotype that will then be validated in the appropriate biological systems. This study has two global objectives. Firstly, we will clarify role of KD mutations for disease progression of CML. Given that the mechanisms responsible for progression of CML form the chronic phase to accelerated and blastic phase are poorly understood, this will increase the knowledge of CML biology. Secondly, we will identify mediators that significantly affect transformation potency in a tightly controlled experimental system. Using this approach, we aim to identify novel therapeutic targets that could be exploited for the treatment of CML, and further, for other types of cancer for which there are currently no effective therapies available. Some patients with chronic myeloid leukemia relapse on therapy with imatinib (Gleevec), because they develop mutations in a critical protein. There is evidence that some of these mutations may also contribute to leukemia progression and confer a very bad prognosis to patients. We will study precisely how the mutations make the leukemia more aggressive, with the aim of identifying proteins that are critical in mediating the more aggressive behavior. Such crucial proteins may then be exploited as drug targets for the treatment of chronic myeloid leukemia, and further, for other types of cancer.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL082978-01
Application #
7023474
Study Section
Special Emphasis Panel (ZHL1-CSR-I (S2))
Program Officer
Di Fronzo, Nancy L
Project Start
2005-09-20
Project End
2009-08-31
Budget Start
2005-09-20
Budget End
2006-08-31
Support Year
1
Fiscal Year
2005
Total Cost
$343,125
Indirect Cost
Name
Oregon Health and Science University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Zabriskie, M S; Eide, C A; Yan, D et al. (2016) Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia. Leukemia 30:1418-21
Patel, Ami B; Vellore, Nadeem A; Deininger, Michael W (2016) New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape. Clin Cancer Res 22:1037-47
Davare, Monika A; Vellore, Nadeem A; Wagner, Jacob P et al. (2015) Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Proc Natl Acad Sci U S A 112:E5381-90
Eiring, Anna M; Page, Brent D G; Kraft, Ira L et al. (2015) Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia 29:586-597
Woessner, D W; Eiring, A M; Bruno, B J et al. (2015) A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia. Leukemia 29:1668-75
Agarwal, Anupriya; Mackenzie, Ryan J; Besson, Arnaud et al. (2014) BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein. Blood 124:3260-73
Zabriskie, Matthew S; Eide, Christopher A; Tantravahi, Srinivas K et al. (2014) BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 26:428-442
Kurokawa, Manabu; Ito, Takahiro; Yang, Chih-Sheng et al. (2013) Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells. Proc Natl Acad Sci U S A 110:2300-5
Corbin, Amie S; O'Hare, Thomas; Gu, Zhimin et al. (2013) KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors. Cancer Res 73:5775-86
Khorashad, Jamshid S; Kelley, Todd W; Szankasi, Philippe et al. (2013) BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood 121:489-98

Showing the most recent 10 out of 43 publications